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Studying the influence of brain cathepsin D (EC 3.4.23.5) and high molecular weight (HMW) aspartic endopeptidase (EC 3.4.23.-) on the processing 
of hypothalamic almodulin-binding coronaro-constrictory peptide factors from the p-chain of globin it was found that only HMW aspartic 
endopeptidase generates the fragment 3140 of the p-chain of bovine hemoglobin (Hb) by cleavage of the Leuso-Leu” and Phe40-Phe41 bonds. 
Digestion of the B-chain of globin was performed at 37°C at an enzyme/substrate ratio of 1:80 at pH 3.5 using different times of incubation (from 
4 h to 10 h). The resulting peptides were separated by reversed-phase high-performance liquid chromatography (HPLC) and then identified by 
amino acid analysis and Edman degradation. The differences in specificity and activity of these two brain aspartic proteinases could be explained 
by their different structural features. Our finding provides evidence for a different biological function of these two enzymes. Data obtained give 
us reason to suppose that HMW aspartic proteinase probably can participate in the processing of the coronaro-constrictory peptide in vivo by 
limited proteolysis of Hb or Hb-like protein. 
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1. INTRODUCTION 
Recently it has been found that 5 calmodulin-binding 
coronaro-constrictory peptide factors (PF,,) isolated 
from bovine hypothalamus represent he fragments 33- 
37, 33-38, 32-38, 32-39, 3140 of the B-chain of Hb 
[1,21. 
Earlier it has been established that these peptides play 
an important role in the regulation of some Ca”, cal- 
modulin (CaM)-dependent enzymes activity, such as 
myosin light chain kinase (MLCK), 3’5’ CAMP 
phosphodiesterase and calcineurin [3,4]. It was shown 
that PF,_, enhanced the contraction in rabbit aortic 
strips in a K’-depolarized mixture (approximately to 
20-25%) and stimulated platelet aggregation induced by 
5 PM ADP (approximately to 25-30%) too. Stimulation 
of these processes accounts for MLCK activation by the 
CaM-PF complex. The K,, value for the CaM-PF com- 
plex (2-10 nM) has been determined [5]. 
It is known that fragments 34-37 and 34-38 of the 
/?-chain of Hb (so-called hemorphins) obtained by enzy- 
matic treatment of the B-chain of Hb have opioid activ- 
ity [6]. Two opioid peptides corresponding to the se- 
quence 3140 and 32-40 of the p-chain of bovine Hb 
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were isolated from bovine Hb peptic hydrolysate [7]. 
Recently an opioid peptide called LW-hemorphin-6, 
corresponding to the sequence at position 3240 of the 
B-chain of human Hb was reported to inhibit the angio- 
tensin converting enzyme activity (ACE) [8]. This pep- 
tide was originally isolated from human pituitary gland. 
These data support our finding since it is very likely, 
that LW-hemorphind corresponding to the sequence 
3240 of the p-chain of human Hb, which contains the 
coronaro-constrictory peptide sequences, can compete 
with angiotensin II (a strong vasoconstrictor agent) by 
inhibition of ACE activity. 
The peptide designed LW-hemorphin-7 identical to 
the sequence 3241 of the /?-chain of human Hb has 
been isolated from cerebrospinal fluid (CSF) of patients 
with cerebrovascular bleeding [9]. 
It can be noticed that all above mentioned biologi- 
cally active peptides, whatever their source, originated 
from the same region of the B-chain of Hb (residue 
3241 of human and residue 31-40 of bovine Hb). 
These data suggest hat Hb or a Hb-like protein is a 
precursor of biologically active peptides which can be 
formed in the organism during physiological or patho- 
physiological processes as a result of limited proteolysis. 
Therefore the study of the processing of coronaro- con- 
strictory peptides from the /?-chain of Hb under the 
influence of two intracellular aspartic endopeptidases 
(cathepsin D and HMW aspartic proteinase) seemed to 
be advisible. We decided to use these enzymes since it 
is known that cathepsin D, the main intracellular aspar- 
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tic proteinase, plays an important role in the breakdown 
of proteins in normal cells and also in the pathological 
processes of tissue breakdown [lo]. Its action can lead 
to the formation of physiologically active peptides from 
their precursors by limited proteolysis [ 11,123. 
HMW aspartic proteinase (& about 90 kDa) with 
properties similar to cathepsin D (substrate specificity, 
sensitivity to pepstatin, pH activity profile) has been 
classified by one group as a cathepsin E-like enzyme, by 
others as a dimer or precursor of cathepsin D and also 
as a cathepsin D-like enzyme [13-161. 
It was shown that in contrast to cathepsin D HMW 
aspartic proteinase from bovine brain generates acardi- 
oactive neurohormone ‘C’ from its protein precursor 
1171. 
In this work, using HPLC, amino acid analysis and 
Edman degradation for the identification of the prod- 
ucts of enzymatic hydrolysis, we have found that HMW 
aspartic proteinase (but not cathepsin D) generates the 
coronaro-constrictory peptide (or LW-hemorphin-7) 
which corresponds to the sequence at position 31-40 of 
the B-chain of bovine Hb (residue 32-41 of the /?-chain 
of human Hb). 
2. MATERIALS AND METHODS 
Cathepsin D and HMW aspartic proteinase were purified from 
bovine brain cortex to apparent homogeneity by a procedure involving 
ammonium sulfate precipitation (30-70%), gel-filtration on Sephadex 
G-100 and affinity chromatography on pepstatin-Agarose [17]. All 
procedures were carried out at 4°C. Endopeptidases activity during 
purification was assayed at pH 3.2 with pyridoxal-Hb as substrate [18]. 
A typical enzyme assay was performed in 0.6 ml of reaction mixture, 
containing 0.05 M citrate buffer, pH 3.2, 100 ,ug of pyridoxal-Hb and 
various amounts of cathepsin D or HMW aspartic proteinase. After 
incubation at 37°C for 1 h with stirring, the reaction was stopped by 
the addition of 0.15 ml of 30% trichloroacetic acid. After centrifuga- 
tion the pH of the supernatant was adjusted to 5.5 with 1 M sodium 
citrate buffer, pH 7,l and the fluorescence was measured at 410 nm 
(excitation at 330 mn) on a fluorescence spectrophotometer (F-2000, 
Hitachi, Ltd., Tokyo, Japan). As controls the substrate and the en- 
zyme were incubated separately. One unit of enzyme activity is defined 
as the amount of enzyme releasing phosphopyridoxyl peptide with 
fluorescence qual to that of 1 nmol of pyridoxamine under the assay 
conditions. 
Digestion of the B-chain of globin was performed at 37°C at an 
enzyme/substrate ratio of 1:80 (w/w) at 37”C, at pH 3.5 using different 
times of incubation (from 4 h to 10 h). For the assay, 0.1 ml of reaction 
mixture, containing 0.05 M citrate buffer, pH 3.5,2Opg of the/?-chain 
of globin and 0.25 pg enzyme was used. The reaction was stopped by 
the addition of 0.025 ml of 30% formic acid. The peptide mixture was 
separated by reversed-phase HPLC on LiChrospher RP-18 (4 
mm x 125 mm, 5 pm) column with a 60 min linear gradient of O-60% 
acetonitrile containing 0.1% trifluoroacetic acid, flow rate 1 ml/min, 
absorbance was measured at 206 nm. 
Amino acid analysis was done by the pre-column o-phthaldialde- 
hyde derivatization method [19]. Amino acid sequence analysis was 
performed on a 2020 gas-phase sequencer equipped with an on-line 
PTH Analyser System Gold (Both Beckman, Fullerton, CA) using the 
conditions recommended by the manufacturer. 
Solid phase peptide synthesis was carried out on a synthesizer (Ap- 
plied Biosystems Model 430 A) using the Fmoc procedure [20]. 
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3. RESULTS AND DISCUSSION 
The influence of brain cathepsin D and HMW-aspar- 
tic proteinase on the /?-chain of bovine globin was stud- 
ied at 37°C at pH 3.5 at an enzyme/substrate ratio of 
1:80. Variation of the incubation time (from 4 h to 10 
h) did not change the set of major peptides in the mix- 
ture as judged from respective chromatographic pro- 
files. Figs. 1 and 2a demonstrate the HPLC profile of 
the /?-chain of globin digestions by cathepsin D and 
HMW aspartic proteinase, respectively. As can be no- 
ticed from these figures the influence of cathepsin D and 
HMW aspartic proteinase on the p-chain of globin is 
different. This difference can be explained by the cleav- 
age of susceptible bonds at different sites of the p-chain 
of globin. 
The resulting peptides were separated by reversed- 
phase HPLC and characterized by amino acid analysis. 
Subsequently the fractions which had amino acid com- 
position similar to fragment 3140 of the B-chain of 
globin were analysed by N-terminal sequence analysis. 
Data obtained revealed that only HMW aspartic pro- 
teinase (but not cathepsin D) generates the fragment 
31-40 of the /?-chain of globin (Fig. 2a, fraction 4) by 
cleavage of the Leu3’-Leu31 and Phem-Phe41 bonds of 
the p-chain of bovine globin (Fig. 3). It should be no- 
ticed that the synthetic peptide (Fig. 2b), corresponding 
to the sequence at position 31-40 of the p-chain of 
bovine globin had the same retention time as fraction 
4 (Fig. 2a) using the same HPLC systems as used during 
the purification of the product of enzymatic digestion. 
It is known that in some cases cerebral cathepsin D 
and HMW aspartic proteinases how almost identical 
substrate specificity. It was shown that these two en- 
zymes cleaved the Leu’“-Leu’l bond in the tetrade- 
capeptide renin substrate and Phe7-Phe’ in substance P
[22-231. However, in the case of hydrolysis of the /?- 
Time min 
Fig. 1. HPLC profile of the/?-chain of globin digestion by bovine brain 
cathepsin D. Separation was done on a LiChrospher RP-18 (4 
mm x 125 mm, 5 pm) column with a 60 min linear gradient of O-60% 
acetonitrile, containing 0.1% trifluoroacetic acid at a flow rate of 1 
ml/min. The absorbance was measured at 206 nm. 
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chain of bovine globin these two aspartic endopepti- 
dases have differences in their specificities. As men- 
tioned above HMW aspartic proteinase in contrast to 
cathepsin D also generates the cardioactive neu- 
rohormone ‘C’ from its protein precursor [17]. These 
findings provide evidence for a different biological func- 
tion of two brain aspartic endopeptidases. Brain HMW 
aspartic proteinase shares a number of properties with 
cathepsin D (sensitivity to pepstatin, substrate specific- 
ity, pH activity profile) and shows partial immunologi- 
cal identity; HMW aspartic proteinase has a specific 
activity 7-10 times lower than that of cathepsin D [24]. 
Until the present ime it is not clear, whether the HMW 
aspartic proteinase is a dimer or a precursor of cathep- 
sin D or an individual enzyme. The differences in spec- 
ificity and activity of these two enzymes may be ex- 
plained by their different structural features. 
Thus, data obtained give us reason to suppose that 
Hb itself or a Hb-like protein is the precursor of the 
coronaro-constrictory peptide (or LW-hemorphin-7) 
which can be formed in the organism during physiolog- 
ical or pathophysiological processes as a result of lim- 
ited proteolysis of this protein by HMW aspartic pro- 
teinase. Furthermore it can be speculated that this pep- 
tide can be metabolized into shorter fragments (like 
PF,,, hemorphin-4, hemorphin-5 etc.) by involving the 
cascade system of different types of intracellular pro- 
teinases, such as metalloendopeptidase ( nkephalinase 
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Fig. 2. HPLC profile of the digestion mixture of the&chain of globin 
by bovine brain HMW aspartic proteinase (a) and of the synthetic 
peptide (Leu-Val-Val-Tyr-Pro-Trp-Thr-Gln-Arg-Phe) (same condi- 












Fig. 3. Complete amino acid sequence of the B-chain of bovine hemo- 
globin [21]. The coronaro-constrictory peptide derived from the j?- 
chain of globin under the influence of bovine brain HMW aspartic 
proteinase by the cleavage of the Let?-Leu” and Phe40-Phe4’ bonds 
is boxed. 
EC 3.4.22.-) [26] or cathepsin B (EC 3.4.22.1) taking 
into account its dipeptidyl carboxypeptidase properties 
~271. 
Until present PF1_5, LW-hemorphin-6 and LW- 
hemorphin-7 were isolated only from bovine and por- 
cine hypothalamus [1,28], human pituitary glands [8] 
and CSF of patients with cerebrovascular bleedings [9]. 
Therefore we cannot exclude the possibility of the exist- 
ence of a Hb-like protein in nervous tissue which can be 
a precursor of these peptides. In the same time since 
erythrocyte membranes contain the HMW aspartic pro- 
teinase [161, it seems more likely that in some physiolog- 
ical or pathological processes this enzyme can partici- 
pate in processing of the above mentioned biologically 
active peptide from Hb. It is known that in certain areas 
of the brain (hypothalamus, pituitary etc.) endothelial 
cells do not form tight junctions and allow a free ex- 
change of molecules between the blood and adjacent 
neurons [29]. Taking into consideration this fact, one 
can suppose that the decapeptide Leu-Val-Val-Tyr-Pro- 
Trp-Thr-Gln-Arg-Phe derived from Hb by HMW as- 
partic proteinase can enter the hypothalamus and par- 
ticipate in the regulation of some metabolic processes 
of nervous tissue. 
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